Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?

Daniël H van Raalte; C Bruce Verchere

doi:10.1016/j.tem.2016.04.009

Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?

Trends Endocrinol Metab. 2016 Jul;27(7):442-445. doi: 10.1016/j.tem.2016.04.009. Epub 2016 May 6.

Authors

Daniël H van Raalte¹, C Bruce Verchere²

Affiliations

¹ Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; Department of Pathology and Laboratory Medicine, Child and Family Research Institute, The University of British Columbia, Vancouver, Canada. Electronic address: d.vanraalte@vumc.nl.
² Department of Pathology and Laboratory Medicine, Child and Family Research Institute, The University of British Columbia, Vancouver, Canada; Department of Surgery, Child and Family Research Institute, The University of British Columbia, Vancouver, Canada.

PMID: 27160799
DOI: 10.1016/j.tem.2016.04.009

Abstract

Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells. We discuss the concepts of beta cell protection versus exhaustion for different GLP-1R agonists based on recent data.

Keywords: Glucagon-like peptide (GLP)-1 receptor agonists; beta-cell exhaustion; beta-cell protection; chronic treatment; insulin secretion.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Glucagon-Like Peptide 1 / analogs & derivatives
Glucagon-Like Peptide 1 / pharmacology*
Glucagon-Like Peptide-1 Receptor / agonists*
Glucagon-Like Peptide-1 Receptor / metabolism*
Humans
Insulin / metabolism
Insulin-Secreting Cells / drug effects*
Insulin-Secreting Cells / metabolism*
Signal Transduction / drug effects

Substances

Glucagon-Like Peptide-1 Receptor
Insulin
Glucagon-Like Peptide 1

Grants and funding

CIHR/Canada